Colon and Rectal Cancer: Aspirin’s Role in Prevention

Colon and rectal cancer is a serious disease affecting millions worldwide, with approximately two million people diagnosed annually. Notably, up to 40% of patients may experience disease progression to advanced stages with metastasis, making treatment more challenging and reducing survival rates.

Exploring Aspirin’s Role in Preventing Cancer Recurrence

Previous research suggests that aspirin may play a role in reducing the risk of certain cancers and could help prevent the recurrence of colon and rectal cancer in patients with mutations in genes associated with the PIK3 signaling pathway. These genes are crucial in regulating cell growth and division.

When mutations occur in these genes, regulatory processes can lose control, allowing cells to proliferate abnormally and form tumors. Although evidence from previous studies was inconsistent, the randomized clinical trial ALASCCA confirmed aspirin’s role, with results published in the New England Journal of Medicine.

ALASCCA Trial: A Landmark Study

The study involved over 3,500 colon and rectal cancer patients across 33 hospitals in Sweden, Norway, Denmark, and Finland. Participants with a specific mutation in the PIK3 pathway were randomly assigned to receive either 160 mg of aspirin daily or a placebo for three years post-surgery.

For those with the genetic mutation, aspirin proved effective in reducing the risk of cancer recurrence by 55% compared to the placebo group.

Professor Anna Martling, the lead author of the trial, states that aspirin is being tested here in an entirely new context as a precision treatment, illustrating how genetic information can be used to tailor treatment, conserve resources, and reduce suffering.

How Does Aspirin Work Against Cancer?

Researchers propose that aspirin’s protective effect is due to multiple biological mechanisms. The drug is known to reduce inflammation, limit platelet activity, and inhibit tumor growth. These effects work together to make the body less conducive to cancer recurrence.

Although all molecular links are not yet understood, the results strongly support the biological basis and suggest that the treatment may be particularly effective in genetically defined subgroups of patients, says Martling.

According to the research team, these findings could impact colorectal cancer treatment strategies worldwide. Martling emphasizes that one of aspirin’s greatest advantages is its wide availability.

Conclusion

The results of the ALASCCA trial mark an important step toward using aspirin as a precision treatment in the context of colorectal cancer, especially for those with certain genetic mutations. This achievement opens new horizons for personalized treatment and offers an effective, economical alternative compared to complex modern drugs. As research continues, aspirin may become an integral part of future cancer treatment protocols.